# A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

Source: https://onco.cc/trials/nct07220616/  
OnCo record `nct07220616` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DS3790a in non-Hodgkin lymphoma, run by Daiichi Sankyo, now recruiting.

## Summary

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies is a phase 1/2 interventional study registered as NCT07220616 by Daiichi Sankyo, with 420 participants planned, started 2026-01-16 and due to reach its primary completion in 2030-11-30. Interventions recorded: DS3790a and Combination drug.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07220616
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies
- Sponsor: Daiichi Sankyo
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07220616: https://clinicaltrials.gov/study/NCT07220616

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct07220616.json